Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
Author:
Ludwig HeinzORCID, Boccadoro MarioORCID, Moreau Philippe, San-Miguel Jesus, Cavo Michele, Pawlyn CharlotteORCID, Zweegman Sonja, Facon Thierry, Driessen Christoph, Hajek RomanORCID, Dimopoulos Melitios A., Gay Francesca, Avet-Loiseau Hervé, Terpos EvangelosORCID, Zojer Niklas, Mohty Mohamad, Mateos Maria-VictoriaORCID, Einsele HermannORCID, Delforge Michel, Caers Jo, Weisel Katja, Jackson Graham, Garderet Laurent, Engelhardt Monika, van de Donk Niels, Leleu Xavier, Goldschmidt Hartmut, Beksac MeralORCID, Nijhof Inger, Abildgaard Niels, Bringhen Sara, Sonneveld Pieter
Abstract
AbstractVaccination is one of the most successful medical interventions that has saved the life of millions of people. Vaccination is particularly important in patients with multiple myeloma, who have an increased risk of infections due to the disease-inherent immune suppression, and because of the immune suppressive effects of therapy. Hence, all appropriate measures should be exploited, to elicit an effective immune response to common pathogens like influenza, pneumococci, varicella zoster virus, and to those bacteria and viruses (haemophilus influenzae, meningococci, and hepatitis) that frequently may pose a significant risk to patients with multiple myeloma. Patients after autologous, and specifically after allogeneic transplantation have severely reduced antibody titers, and therefore require a broader spectrum of vaccinations. Response to vaccination in myeloma often is less vigorous than in the general population, mandating either measurement of the postvaccination antibody titers and/or repeating the vaccination. Here, we compile the existing data on vaccination in multiple myeloma and provide recommendations for clinical practice.
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference84 articles.
1. Alemu A, Singh M, Blumberg C, Richards JO, Oaks MK, Thompson MA. Multiple myeloma vaccination patterns in a large health system: a pilot study. J Patient Cent Res Rev. 2017;4:53–9. 2. Brioli A, Klaus M, Sayer H, Scholl S, Ernst T, Hilgendorf I, et al. The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey. Ann Hematol. 2019;98:713–22. 3. Kristinsson SY, Tang M, Pfeiffer RM, Bjorkholm M, Goldin LR, Blimark C, et al. Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica. 2012;97:854–8. 4. Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bjorkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100:107–13. 5. National Center for Immunization and Respiratory Diseases, General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP): Altered Immunocompetence. 2019. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html. Accessed 1 Mar 2020.
Cited by
78 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|